JOURNAL OF BUON, vol.16, no.4, pp.759-764, 2011 (SCI-Expanded)
Purpose: Sorafenib has been found to have significant clinical activity against hepatocellular carcinoma (HCC). Hand-foot skin syndrome (HFS) has been described with the usage of sorafenib. It is a dose-limiting toxicity and may lead to compromised efficacy because of dose reduction.